These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19128229)

  • 21. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
    Patel MD; Katz SD
    Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.
    Köhler TS; McVary KT
    Eur Urol; 2009 Jan; 55(1):38-48. PubMed ID: 18783872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism].
    Mazo EB; Gamidov SI; Sotnikova EM
    Ter Arkh; 2008; 80(12):59-63. PubMed ID: 19227909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
    DeBusk RF
    Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient.
    Kloner RA
    Endocrine; 2004; 23(2-3):125-9. PubMed ID: 15146090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between hypogonadism and erectile dysfunction.
    Hwang TI; Lin YC
    Int J Impot Res; 2008; 20(3):231-5. PubMed ID: 18305486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.
    de Tejada IS
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S40-2. PubMed ID: 15224136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erectile dysfunction in aging men: testosterone role in therapeutic protocols.
    Caretta N; Ferlin A; Palego PF; Foresta C
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):108-11. PubMed ID: 16760637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes.
    Zhang XH; Filippi S; Morelli A; Vignozzi L; Luconi M; Donati S; Forti G; Maggi M
    J Sex Med; 2006 Mar; 3(2):253-64; discussion 264-5, author reply 265-6. PubMed ID: 16490018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
    Nehra A
    Mayo Clin Proc; 2009 Feb; 84(2):139-48. PubMed ID: 19181648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
    Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
    BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase type 5 inhibithors in older males.
    Frajese GV; Pozzi F
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins and erectile dysfunction: a critical summary of current evidence.
    La Vignera S; Condorelli RA; Vicari E; Calogero AE
    J Androl; 2012; 33(4):552-8. PubMed ID: 22052777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of the association between erectile dysfunction and cardiovascular disease.
    Gandaglia G; Briganti A; Jackson G; Kloner RA; Montorsi F; Montorsi P; Vlachopoulos C
    Eur Urol; 2014 May; 65(5):968-78. PubMed ID: 24011423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vardenafil: a review of its use in erectile dysfunction.
    Keating GM; Scott LJ
    Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.